Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atorvastatin and N-acetylcysteine for poor graft function or relapsed/refractory aplastic anaemia
ACTRN12620001339943Phase 2Recruiting
- Sponsor
- Royal Melbourne Hospital
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of atorvastatin and acetylcysteine in poor graft function (PGF) and aplastic anemia (2 arms), sponsored by Royal Melbourne Hospital. Primary endpoints: Complete response and Incidence of non-haematological adverse events. Started Sep 2021; status: recruiting.
02
Drugs
atorvastatinacetylcysteine
03
Conditions
poor graft function (PGF)aplastic anemia
Beyond the preview
Go deeper on ACTRN12620001339943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620001339943.